High-Quality Scientific Narratives for Global Submissions
At Indivirtus Healthcare Services Pvt. Ltd., our Clinical and Nonclinical Overview services deliver expertly crafted Module 2.4 (Nonclinical Overview) and Module 2.5 (Clinical Overview) documents, along with bioequivalence justifications and BCS biowaiver support. We ensure ICH-compliant, submission-ready narratives for global regulatory approvals.
Our services include preparation of ICH-compliant Module 2.4 and 2.5 documents, bioequivalence justifications, BCS biowaiver support, and bridging study reports, ensuring robust scientific narratives for global submissions.
High-quality overviews provide the scientific foundation for Modules 3–5, ensuring regulatory acceptance, compliance, and streamlined approval processes for pharmaceuticals.
As a trusted CRO, Indivirtus Healthcare Services delivers expert-led overview solutions, providing scientifically sound and compliant narratives to support successful dossier submissions.
At Indivirtus Healthcare Services, our Clinical and Nonclinical Overview services are led by certified regulatory and scientific experts with global submission expertise. We compile Module 2.4 (Nonclinical Overview) and Module 2.5 (Clinical Overview), develop bioequivalence justifications, and provide BCS biowaiver support for Class I/III drugs.
Our structured approach ensures submission-ready documents, aligning with ICH M4S, US FDA, EMA, ASEAN, and CDSCO guidelines, delivering robust narratives and bridging study reports for global regulatory approvals.
Module 2.4 (Nonclinical Overview): Comprehensive nonclinical summary for regulatory dossiers.
Module 2.5 (Clinical Overview): Detailed clinical summary supporting safety and efficacy.
Bioequivalence Justification Document: Scientific rationale for bioequivalence claims.
BCS-Based Biowaiver Support: Documentation for Class I/III biowaiver applications.
Bridging Study Summary Report: Reports to support global submission requirements.
Our Clinical and Nonclinical Overview services align with stringent global standards, ensuring your documents are submission-ready and compliant with international regulatory expectations. By adhering to industry-leading guidelines, we deliver solutions that enhance approval success.
Our Clinical and Nonclinical Overview services are essential for pharmaceutical companies preparing global regulatory submissions. Ideal for new drugs, generics, and biosimilars, our solutions support dossier acceptance and approval. Key use cases include compiling overviews for FDA/EMA submissions, justifying bioequivalence for generics, and securing BCS biowaivers for Class I/III drugs.
Indivirtus Healthcare Services is a trusted partner for pharmaceutical companies, delivering expert-led overview solutions backed by certified regulatory and scientific professionals with global experience. Our services ensure scientifically defensible outcomes, rapid delivery, and strict confidentiality to protect your proprietary information.
With a commitment to industry best practices, we empower your organization with compliant, high-quality narratives, driving regulatory success and market authorization.
Module 2.4 includes the nonclinical overview summarizing pharmacology and toxicology, while Module 2.5 includes the clinical overview with efficacy and safety conclusions.
BCS-based biowaivers are regulatory provisions that allow waiving in vivo bioequivalence studies for highly soluble, highly permeable (Class I) or rapidly dissolving (Class III) drugs.
Yes, we evaluate fixed-dose combination products for eligibility under biowaiver guidance and prepare appropriate justification based on regulatory expectations.
Bridging study reports are summaries that link nonclinical or clinical data from different sources to justify product approval in a new population or region.
Yes, all overviews include updated literature references, citations from global guidance documents, and rationale to support conclusions.
Our services include preparation of Module 2.4 and 2.5 documents, bioequivalence justifications, BCS biowaiver support, and bridging study reports for global submissions.
Pharmaceutical companies preparing regulatory dossiers for new drugs, generics, or biosimilars benefit from our tailored overview solutions.
Our services align with ICH M4S, US FDA, EMA, ASEAN biowaiver guidelines, and CDSCO BA/BE norms, ensuring global regulatory compliance.
Clients receive Module 2.4 and 2.5 documents, bioequivalence justifications, BCS biowaiver support, and bridging study reports.
Yes, our services are tailored to your specific product, regulatory requirements, and submission goals, ensuring compliant solutions.
We provide scientific justifications for bioequivalence and BCS-based biowaiver support for Class I/III drugs, ensuring robust regulatory submissions.